Understanding the complex processes involved in the development of cutaneous T-cell lymphoma (CTCL) is critical for improving treatment options. Protheragen's scientists are focused on understanding CTCL pathogenesis to identify potential therapeutic targets. We intend to lead in the creation of new therapies that will effectively treat CTCL by specifically targeting the mechanisms that drive the disease.
A form of non-Hodgkin lymphoma is known as cutaneous T-cell lymphoma (CTCL). It is described by a malignant proliferation of T-cells with skin-homing properties and is divided into a number of subtypes. Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes that have unique clinical and molecular features.
| Subtypes | Causes | Incidence |
|---|---|---|
| Mycosis fungoides (MF) |
|
50%-70% of CTCL cases |
| Sézary syndrome (SS) |
|
<5% of CTCL cases |
Cutaneous T-cell lymphoma (CTCL) is the result of neoplastic change of skin-homing memory T-cells which is driven by the mutations in TP53, STAT3/STAT5, DNMT3A, epigenetic changes, and chronic antigenic stimulation. The immune evasion process within the tumor microenvironment is accomplished due to the Th2 polarization, PD-1/TOX overexpression, and regulatory T-cell infiltration.
Fig.1 Role of cytokines in the development of a Th2-biased inflammatory milieu through the modulation of chemokines. (Patil, Kalyani, et al., 2022)
The market for cutaneous T-cell lymphoma (CTCL) was valued at USD 443.4 million in 2024 and is expected to grow at a CAGR of 3.68% from 2025 to 2035, reaching USD 658.8 million by 2035. The therapeutic management of CTCL is challenging due to the plethora of disease subtypes and the development of resistance pathways. This shows persistent gaps and opportunities in innovation to improve the treatment paradigm associated with CTCL.
| Drug Names | Mechanism of Action | Targets | NCT Number | Research Phase |
|---|---|---|---|---|
| IPH4102 | Induces antibody-dependent cellular cytotoxicity (ADCC) against malignant T-cells | KIR3DL2 | NCT02593045 | Phase II |
| Bexarotene | Modulates gene expression, induces apoptosis, and inhibits proliferation | RXRs | NCT05296304 | Approved |
| E7777 | Binds to IL-2R and delivers toxin to kill malignant T-cells | IL2RA | NCT02676778 | Approved |
| AFM13 | Engages NK cells for ADCC against CD30+ tumor cells | CD16a x CD30 | NCT03192202 | Phase II |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Protheragen pledges to provide advanced diagnostic and therapeutic development service for the complex lymphoproliferative disorder, cutaneous T-cell lymphoma (CTCL). Our focus is on the development of multifaceted innovative therapies which are precisely evaluated in sophisticated disease models.
Specializing in preclinical research for drug development, Protheragen offers a comprehensive solution that includes pharmacodynamics (PD), pharmacokinetic (PK) and toxicology studies to thoroughly validate and optimize therapies for cutaneous T-cell lymphoma (CTCL). If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
Myeloproliferative Disorders (MPDs)
Bone Marrow Failure Syndromes (BMFS)